The world is in the midst of a COVID-19 pandemic. As WHO and partners work together on the response – tracking the pandemic, advising on critical interventions, distributing vital medical supplies to those in need – they are racing to develop and deploy safe and effective vaccines. 

Vaccines save millions of lives each year. Vaccines work by training and preparing the body’s natural defences – the immune system – to recognize and fight off the viruses and bacteria they target. If the body is exposed to those disease-causing germs later, the body is immediately ready to destroy them, preventing illness.


Sinopharm Vaccine

  • For the prevention of 2019 coronavirus disease (COVID-19) for individuals 16 years of age and older

  • SARS-CoV-2 Vaccine (Vero cell), Inactivated

  • The hepatitis A vaccine Healive® is the first HepA vaccine in China to pass WHO-PQ, and is being exported to more than 10 “Belt and Road” countries and international organizations such as UNICEF and PAHO.

Worldwide Market & Footprint 

  • Sinopharm’s vaccine has been sold in 22 countries around the world, has been registered in 17 countries, and is being registered in 26 countries, covering 3.25 billion people 68 million newborns

  • The cumulative global sales are nearly 160 million doses. In 2019, an average of 112 people per minute were vaccinated with Sinopharm’s vaccines to obtain immune protection.

Quality Accreditation

  • Total GMPs: 11 Certificates  

  • Total MAs: 33 product Certificates 

  • Qualified by WHO PQ, China, Kazakhstan, Nepal, Nigeria, Argentina(PIC/s), Turkey(PIC/s), Thailand(PIC/s), Cuba,  WHO PQ


Buy-up Int’l Trading Co., Ltd 

Flt 7B10, 7/F, Blk B, Cheong Wah Fty Bldg, 39-41 Sheung Heung Road, Tokwawan, Kowloon, Hong Kong

+852-67271863 (WhatsApp only)

  • White Facebook Icon
  • White LinkedIn Icon

© 2021 My Medical Source.

Quality Accreditation